Results 41 to 50 of about 15,408 (221)

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

Sabin polio virus protein 1 (VP1) evolution in patients with acute flaccid paralysis from 2010 to 2016 in Uganda

Virology Journal, 2023
Acute flaccid paralysis (AFP) is a rare side effect of the oral polio vaccine but can be associated with outbreaks and permanent disability in patients harboring circulating vaccine-derived polioviruses (cVDPVs).
Mary Bridget Nanteza, Barnabas Bakamutumaho, Phionah Tushabe, Prossy Namuwulya, Molly Birungi, Rajab Dhatemwa, James Peter Eliku, Mayi Tibanagwa, Proscovia Kakooza, Henry Bukenya, Josephine Bwogi, Charles Rutebarika Byabamazima   +11 more
doaj   +1 more source

Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan

Vaccines, 2023
The oral poliovirus vaccine (OPV) has been the mainstay of polio eradication, especially in low-income countries, and its use has eliminated wild poliovirus type 2.
Muhammad Atif Habib, Sajid Bashir Soofi, Imtiaz Hussain, Imran Ahmed, Zamir Hussain, Rehman Tahir, Saeed Anwar, Simon Cousens, Zulfiqar A. Bhutta   +8 more
doaj   +1 more source

Hospital discharges-based search of acute flaccid paralysis cases 2007-2016 in Italy and comparison with the National Surveillance System for monitoring the risk of polio reintroduction [PDF]

, 2019
Background: Acute flaccid paralysis (AFP) surveillance has been adopted globally as a key strategy for monitoring the progress of the polio eradication initiative.
Affanni P., Amato C., Ansaldi F., Arghittu A., Bellino S., Binda S., Bonaccorsi G., Brusaferro S., Buttinelli G., Camilloni B., Capannolo B., Carraro V., Castiglia P., D'errico M.M., De Grazia S., De Stefano C., Fiore S., Foca A., Fontana S., Germinario C., Giammanco G., Grasso G.M., Larocca A., Lombardi D., Lorini C., Mancini C., Napoletano G., Pellegrinelli L., Pennino F., Russo F., Spertini S., Stefanelli P., Triassi M., Vairo F., Veronesi L., Zanella F.   +35 more
core   +5 more sources

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention

MedComm, Volume 7, Issue 1, January 2026.
The review manuscript examines the molecular pathogenesis, screening, prevention advances, and evolving targeted therapies in breast cancer. It highlights the integration of AI and multiomics for precision prevention and personalized treatment, pointing toward future directions in equitable cancer care.
Huijun Lei, Jinzhen Fu, Wei Gu, Hongjin Qiao, Huixue Guo, Zijian Chen, San Ming Wang, Tianhui Chen   +7 more
wiley   +1 more source

Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022

Emerging Infectious Diseases
Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine.
Farrell A. Tobolowsky, Fred Nsubuga, Zunera Gilani, Annet Kisakye, Helen Ndagije, Daniel Kyabayinze, Jane F. Gidudu   +6 more
doaj   +1 more source

Poliovirus vaccination during the endgame: insights from integrated modeling

Expert Review of Vaccines, 2017
Introduction: Managing the polio endgame requires access to sufficient quantities of poliovirus vaccines. After oral poliovirus vaccine (OPV) cessation, outbreaks may occur that require outbreak response using monovalent OPV (mOPV) and/or inactivated ...
Radboud J. Duintjer Tebbens, Kimberly M. Thompson   +1 more
doaj   +1 more source

Acute flaccid paralysis with anterior myelitis - California, June 2012-June 2014. [PDF]

, 2014
In August 2012, the California Department of Public Health (CDPH) was contacted by a San Francisco Bay area clinician who requested poliovirus testing for an unvaccinated man aged 29 years with acute flaccid paralysis (AFP) associated with anterior ...
Ayscue, Patrick, Centers for Disease Control and Prevention (CDC), Clayton, Anna, Feikin, Daniel, Glaser, Carol, Harriman, Kathleen, Nix, William Allan, Padilla, Tasha, Pan, Chao, Reichel, John, Sejvar, James, Sheriff, Heather, Van Haren, Keith, Waldron, Paul, Watt, James, Waubant, Emmanuelle, Yagi, Shigeo, Yen, Cynthia   +17 more
core   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source